Qiagen (QGEN) Tops Q2 EPS by 5c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
July 26, 2022 1:49 PM EDTQ2 2022: Net sales of $516 million (-9% actual rates, -4% CER); diluted EPS of $0.42 and adjusted diluted EPS of $0.51 over year-ago period Net sales of $544 million at CER vs. outlook for at least $510 million CER, adjusted diluted EPS of $0.53 CER vs. outlook for at least $0.46 CER Non-COVID sales rise 10% CER to $423 million, and up 15% CER excluding Q2 2021 genomics technology sale; COVID-19 sales decline 39% CER H1 2022 operating cash flow +33% to $379 million, free cash flow +63% to $318... More
